News & Updates

Show Multimedia Only

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

12 Feb 2025 by

When treating patients with locally advanced esophageal squamous cell carcinoma (ESCC) in the neoadjuvant setting, chemoradiotherapy with or without sintilimab results in significantly higher pathological complete response (pCR) rates compared with chemotherapy plus sintilimab, according to preliminary data from the phase III SCIENCE trial from China.

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

12 Feb 2025

Peginterferon α-2b may deter growth, thyroid function in children with CHB

12 Feb 2025 by

Treatment with peginterferon (PegIFN) α-2b appears to inhibit the growth of and thyroid function in children with chronic hepatitis B (CHB), suggests a study.

Peginterferon α-2b may deter growth, thyroid function in children with CHB

12 Feb 2025

Glutamatergic meds beneficial in obsessive-compulsive disorder

12 Feb 2025

Glutamatergic medications appear to be efficacious in the treatment of individuals with obsessive-compulsive disorder, according to the results of a meta-analysis.

Glutamatergic meds beneficial in obsessive-compulsive disorder

12 Feb 2025

Propranolol lowers risk of ischaemic stroke in women with migraine

12 Feb 2025 by

Treatment with propranolol, a non-selective beta-blocker medication widely used to prevent migraines was associated with a significant reduction in the risk of ischaemic stroke in women with migraine, according to a preliminary study presented at ISC 2025.

Propranolol lowers risk of ischaemic stroke in women with migraine

12 Feb 2025

Stroke patients with NSAID allergy labels have poorer treatment outcomes

12 Feb 2025 by

Stroke patients with NSAID allergy labels have significantly higher mortality, peripheral vascular disease (PVD) and major adverse cardiovascular events (MACE) than those not labelled with NSAID allergies, and the rate of mislabelled NSAID allergy is high, a study by the University of Hong Kong (HKU) has found.

Stroke patients with NSAID allergy labels have poorer treatment outcomes

12 Feb 2025

Psilocybin shows promise for treatment-resistant depression

11 Feb 2025 by

The use of single-dose psilocybin offers potential safety and efficacy in patients with severe treatment-resistant depression (TRD), a study has shown.

Psilocybin shows promise for treatment-resistant depression

11 Feb 2025

Abelacimab outperforms rivaroxaban for AF patients at risk of stroke

11 Feb 2025

In the treatment of patients with atrial fibrillation (AF) and moderate-to-high risk of stroke, abelacimab appears more beneficial than rivaroxaban, having been associated with lower free factor XI levels and fewer bleeding events in the phase IIB AZALEA–TIMI 71 study.

Abelacimab outperforms rivaroxaban for AF patients at risk of stroke

11 Feb 2025

Old drugs, new tricks: Repositioning pitavastatin for glioblastoma treatment

11 Feb 2025 by

Nanostructured lipid carriers (NLCs) delivering pitavastatin demonstrated potential for glioblastoma (GB) treatment in a systematic benchtop study.

Old drugs, new tricks: Repositioning pitavastatin for glioblastoma treatment

11 Feb 2025

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

10 Feb 2025

Patients with hepatocellular carcinoma (HCC) who are receiving treatment with the combination of atezolizumab plus bevacizumab may be at risk of variceal bleeding, particularly those with a low platelet count, portal vein invasion, history of gastrointestinal bleeding, and varices needing treatment, as shown in a retrospective study.

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

10 Feb 2025

FMT of no benefit in systemic sclerosis patients with lower GI tract involvement

09 Feb 2025

Faecal microbiota transplantation (FMT) with standardized anaerobic cultivated human intestinal microbiome is safe but does not appear to be efficacious in patients with systemic sclerosis experiencing lower gastrointestinal (GI) tract symptoms, according to a phase II study.

FMT of no benefit in systemic sclerosis patients with lower GI tract involvement

09 Feb 2025

News & Updates

Filter by Specialty:

Specialty:

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

Peginterferon α-2b may deter growth, thyroid function in children with CHB

Peginterferon α-2b may deter growth, thyroid function in children with CHB

Glutamatergic meds beneficial in obsessive-compulsive disorder

Glutamatergic meds beneficial in obsessive-compulsive disorder

Propranolol lowers risk of ischaemic stroke in women with migraine

Propranolol lowers risk of ischaemic stroke in women with migraine

Stroke patients with NSAID allergy labels have poorer treatment outcomes

Stroke patients with NSAID allergy labels have poorer treatment outcomes

Psilocybin shows promise for treatment-resistant depression

Psilocybin shows promise for treatment-resistant depression

Abelacimab outperforms rivaroxaban for AF patients at risk of stroke

Abelacimab outperforms rivaroxaban for AF patients at risk of stroke

Old drugs, new tricks: Repositioning pitavastatin for glioblastoma treatment

Old drugs, new tricks: Repositioning pitavastatin for glioblastoma treatment

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

FMT of no benefit in systemic sclerosis patients with lower GI tract involvement

FMT of no benefit in systemic sclerosis patients with lower GI tract involvement